These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3657380)

  • 1. The effects of L-tryptophan on haloperidol-induced movement disorder in the rat.
    Kozell L; Sandyk R; Wagner GC; Fisher H
    Life Sci; 1987 Oct; 41(14):1739-44. PubMed ID: 3657380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats.
    Dhingra D; Goswami S; Gahalain N
    Nutr Neurosci; 2018 Nov; 21(9):667-675. PubMed ID: 28641484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of tryptophan and valine administration on behavioral pharmacology of haloperidol.
    Ali O; Haleem DJ; Saify ZS; Kamil N; Obaid R; Ahmed SW
    Pak J Pharm Sci; 2005 Apr; 18(2):23-8. PubMed ID: 16431394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-tryptophan in neuroleptic-induced tardive dyskinesia.
    Sandyk R; Bamford CR; Khan I; Fisher H
    Int J Neurosci; 1988 Sep; 42(1-2):127-30. PubMed ID: 2905343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A; Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurochemical and motor effects of high dose haloperidol treatment: exacerbation by tryptophan supplementation.
    Johnson SK; Wagner GC; Fischer H
    Proc Soc Exp Biol Med; 1992 Sep; 200(4):571-5. PubMed ID: 1380718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone attenuates neuroleptic-induced orofacial dyskinesia via the activity of its metabolite, allopregnanolone, a positive GABA(A) modulating neurosteroid.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):451-61. PubMed ID: 17988775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats.
    Kaneda H; Shirakawa O; Dale J; Goodman L; Bachus SE; Tamminga CA
    Eur J Pharmacol; 1992 Feb; 212(1):43-9. PubMed ID: 1555638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association with persistent neuroleptic-induced dyskinesia of regional changes in brain GABA synthesis.
    Gunne LM; Häggström JE; Sjöquist B
    Nature; 1984 May 24-30; 309(5966):347-9. PubMed ID: 6727989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced metabolism and turnover rates of rat brain dopamine, norepinephrine and serotonin by chronic desipramine and zimelidine treatments.
    Karoum F; Korpi ER; Linnoila M; Chuang LW; Wyatt RJ
    Eur J Pharmacol; 1984 Apr; 100(2):137-44. PubMed ID: 6234178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):211-6. PubMed ID: 17520104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of haloperidol on dopamine release and metabolism in caudate putamen and anteromedial frontal cortex using intracerebral dialysis.
    Kurata K; Shibata R
    Pharmacology; 1991; 42(1):1-9. PubMed ID: 2057516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of chronic administration of sarizotan, 5-HT1A agonist/D3/D4 ligand, on haloperidol-induced repetitive jaw movements in rat model of tardive dyskinesia.
    Rosengarten H; Bartoszyk GD; Quartermain D; Lin Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):273-9. PubMed ID: 16229932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible involvement of prostaglandins in haloperidol-induced orofacial dyskinesia in rats.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 Nov; 430(2-3):295-8. PubMed ID: 11711046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain.
    Lappalainen J; Hietala J; Koulu M; Seppälä T; Sjöholm B; Syvälahti E
    J Pharmacol Exp Ther; 1990 Feb; 252(2):845-52. PubMed ID: 2179533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.